

# Predictive factors for sarcopenia and malabsorption in high risk surgical oncological patients after cytoreductive surgery and HIPEC procedure

Published: 20-10-2016

Last updated: 19-03-2025

To investigate the predictive factors for sarcopenia in high risk surgical oncological patients undergoing a CRS + HIPEC procedure. The secondary goal is to investigate the predictive factors for malabsorption and the incidence of anastomic leakage...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Completed
<b>Health condition type</b>	Malignant and unspecified neoplasms gastrointestinal NEC
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON42927

### Source

ToetsingOnline

### Brief title

Sarcopenia and Malabsorption in HIPEC patients (SMAL-HIPEC)

### Condition

- Malignant and unspecified neoplasms gastrointestinal NEC
- Electrolyte and fluid balance conditions

### Synonym

muscle loss and HIPEC procedure

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Universitair Medisch Centrum Groningen

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** Cancer, HIPEC, Malabsorption, Sarcopenia

## Outcome measures

### Primary outcome

Sarcopenia (Muscle loss), measured by the psoas muscle density is the primary outcome

### Secondary outcome

Malabsorption, measured by the fecal energy by bomb calorimetry [kcal/d] is the secondary outcome.

Other endpoints are anastomic leakage, pneumonia, infection, length of hospital stay, readmission rate, and one-year survival.

## Study description

### Background summary

Cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) provides a promising therapeutic strategy for patients with gastrointestinal cancer. Sarcopenia and malabsorption are common in patients after CRS + HIPEC surgery and are associated with an increase on postoperative complications. therefore, this study aims to investigate the predictive factors for sarcopenia and malabsorption in high risk surgical oncological patients undergoing a CRS + HIPEC procedure

### Study objective

To investigate the predictive factors for sarcopenia in high risk surgical oncological patients undergoing a CRS + HIPEC procedure. The secondary goal is to investigate the predictive factors for malabsorption and the incidence of

anastomic leakage, pneumonia, infection and length of hospital stay, readmission rate and survival in these patients, one year after surgery.

## **Study design**

A one-year observational study

## **Study burden and risks**

5x measuring upper arm and handgrip strength  
5x physical examination and questions about nutrition (PG\_SGA) (5 minutes)  
3 x questionnaire quality of life (5 minutes)  
3x collection 24-hour urine  
2x keep their diet steady and notate their food intake during 4 consecutive days and collection of feces on 2nd, 3rd and 4th day (bomb calorimetry)  
2x analysis of oxygen and cardioxide while lying on a bed (15 minutes) (indirect calorimetry)  
3x 2 extra tubes of blood  
Wear a pedometer for 2 days prior to visiting the surgeon

All these test together will take about 3 hours to complete. The blood donation can cause pain and bruising. There is no extra puncture needed for this donation. Keeping the diet steady for 4 consecutive days and collect the stool can be burdensome for the patient.

## **Contacts**

### **Public**

Universitair Medisch Centrum Groningen

Hanzeplein 1  
Groningen 9713 GZ  
NL

### **Scientific**

Universitair Medisch Centrum Groningen

Hanzeplein 1  
Groningen 9713 GZ  
NL

## **Trial sites**

## Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Patients > 18 years that undergo CRS and HIPEC procedure at the University Medical Center Groningen (UMCG)

### Exclusion criteria

All patients not eligible for CRS and HIPEC procedure  
not fit for surgery or  
unable to provide written consent or inability to fill out questionnaires

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

### Recruitment

NL

Recruitment status: Completed

Start date (anticipated): 05-10-2017

Enrollment: 70

Type: Actual

## Ethics review

Approved WMO

Date: 20-10-2016

Application type: First submission

Review commission: METC Universitair Medisch Centrum Groningen (Groningen)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

ID: 28190

Source: Nationaal Trial Register

Title:

### In other registers

Register	ID
CCMO	NL57812.042.16
OMON	NL-OMON28190